Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer

Metastatic Colorectal Cancer Clinical Trial

Official title:

PD-1 Antibody (Tislelizumab) Combined With VEGFR 1/2/3 Inhibitor (Fruquintinib) for ARID1A-mutated Metastatic pMMR/MSS Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05690035
• Other study ID #: SL-B2022-653-01
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: February 2023
• Est. completion date: January 2026

Study information

• Verified date: January 2023
• Source: Sun Yat-sen University
• Contact: Peirong Ding, M.D.
• Phone: 00862087343124
• Email: dingpr[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan. Patients with hypermutated CRC that carries POLE/POLD1 mutations cannot be included.

Description:

In this open-label phase II study, patients with ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with standard chemotherapy that includes fluoropyrimidine, oxaliplatin, and irinotecan, will be scheduled for Tislelizumab (200mg ivdrip Q3W day1) + Fruquintinib (5mg/day Q3W day1-14) until intolerable toxicity, disease progression or death. Primary endpoint of this study is ORR and secondary endpoints are OS, PFS, DCR and safety.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: January 2026
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• 18-80 years old (including 18 and 80);

• Histologically confirmed colorectal adenocarcinoma and biopsy pathology confirmed MSS/pMMR;

• Gene testing confirmed ARID1A gene mutation (nonsynonymous);

• No signs of intestinal obstruction; Or intestinal obstruction has been relieved after proximal colostomy;

• Has received and failed = 2 line of chemotherapy or progressed on or intolerable to oxaliplatin, irinotecan and fluorouracil chemotherapy after diagnosed with mCRC;

• ECOG PS 0-2;

• Able to swallow tablets;

• Life expectancy of greater than 3 months;

• Adequate bone marrow and organ function;

• If female and of childbearing potential, must:

• Have a negative pregnancy test =14 days prior to initiating study treatment

• Agree to avoid pregnancy during and for 3 months after study treatment

If male with a partner of childbearing potential, must:

• Agree to use adequate, medically approved, contraceptive precautions during and for 3 months after the last dose of study treatment.

• Able and willing to provide written informed consent for the study.

Exclusion Criteria:

• Any active autoimmune disease or history of autoimmune disease;

• Those who are using immunosuppressive agents, or systemic or absorbable local hormone therapy to achieve immunosuppressive purpose, and continue to use within 2 weeks before enrollment;

• Severe allergic reaction to other monoclonal antibodies;

• Subjects with clinical symptoms of untreated active brain metastasis or meningeal metastasis;

• Have received other PD-1 antibody therapy or other immunotherapy targeting PD-1/PD-L1 in the past;

• Patients with high TMB (= 30Muts/Mb) and germline or somatic POLE/POLD1 gene mutations in the exonuclease domain;

• There are clinical symptoms or diseases of heart that are not well controlled, such as: (a) heart failure of NYHA level 2 or above (b) unstable angina pectoris (c) myocardial infarction occurred within 1 year (d) clinically significant supraventricular or ventricular arrhythmia needs treatment or intervention;

• Known hereditary or acquired bleeding and thrombophilia or being treated with thrombolysis or anticoagulation;

• Urinary protein = ++, or the 24-hour urine protein quantification greater than 1.0g;

• Clinically significant bleeding symptoms or clear bleeding tendency within 3 months before enrollment;

• Subjects with active infection;

• Congenital or acquired immune deficiency (such as HIV infected persons), or active hepatitis (hepatitis B: HBsAg positive and HBV DNA = 10^4 copies/ml; hepatitis C: HCV antibody positive);

• Other advanced malignant tumors within 5 years (except cured skin basal cell carcinoma, cervical carcinoma in situ, ovarian cancer, thyroid cancer and breast cancer);

• Live vaccine may be inoculated less than 4 weeks before the study medication or during the study period;

• Known or suspected to be allergic to the study drug or to any drug given in this trial;

• Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions that makes the subject not eligible according to the judgment of the investigator.

Related Conditions & MeSH terms

• Colorectal Neoplasms
• mCRC
• Metastatic Colorectal Cancer

Intervention

Drug:
• Tislelizumab & Fruquintinib
combinational treatment of Tislelizumab and Fruquintinib until PD, intolerable toxicity, death or withdrawal of informed consent

Locations

Country	Name	City	State
China	Sun Yat-sen University, Cancer Center	Guangzhou	Guangdong
China	Xiaoshi Zhang	Guangzhou

Sponsors (3)

Lead Sponsor	Collaborator
Sun Yat-sen University	BeiGene, Hutchmed

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	The proportion of patients with a confirmed complete response or partial response	up to 3 years
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from enrollment to the first documented progressive disease (PD) or death due to any cause, whichever occurred first.	up to 3 years
Secondary	Overall Survival (OS)	OS is defined as the time from enrollment to death due to any cause.	up to 3 years
Secondary	Disease control rate	The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD).	up to 3 years
Secondary	Incidence of Treatment-Emergent Adverse Events	Safety and tolerance evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0.	until 60 days after last patient last study drug treatment